

## Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies

Published: 2012-MAY-01

Pages: 6501

Format: PDF

Price: 4495 USD (Single User License)

### Description

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

#### Part I: Apoptosis

The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.

This part is based on the following publication:

Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

#### Part II: Protein Kinase Inhibitors

The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.

This part is based on the following publication:

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

#### Part III: Antibodies

The cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications.

This part is based on the following publication:

The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- \* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- \* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- \* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- \* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

# BioMarket Group - A Global Online Aggregator of Life Science Market Research

\* Supporting development of integrative molecule, pathway and disease area strategies

\* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

## Table of Contents

Key Topics Covered:

### Part I: Apoptosis

5.1	The Scope of this Report	33
6	Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)	37-416
7	Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs)	417-622
8	Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies)	623-660
9	Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications)	661-776
10	Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs)	777-1601
	Disclaimer	1602
11	Drug Index	1603
12	Company Index	1611

Figures: Includes 7 Figures  
Tables: Includes 315 Tables  
Total Number of Pages: 1,617

### Part II: Protein Kinase Inhibitors

5.1	The Scope of this Report	38
6	Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets)	42-516
7	Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs)	517-945
8	Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies)	946-1013
9	Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications)	1014-1223
10	Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs)	1224-2939
11	Disclaimer	2940

Figures: Includes 8 Figures  
Tables: Includes 389 Tables  
Total Number of Pages: 2,940

### Part III: Antibodies

5.1	The Scope of this Report	35
6	Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (255 Drug Targets)	39-430
7	Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug Targets Strategies and 531 Antibody Drugs)	431-768
8	Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications)	769-893
9	Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531 Antibody Drugs)	894-1,916
10	Disclaimer	1917
11	Drug Index	1918
12	Company Index	1934

Figures: Includes 5 Figures  
Tables: Includes 347 Tables  
Total Number of Pages: 1,944

## Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/triple-analysis-apoptosis-protein-kinase-inhibitors-and-antibodies.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

<http://www.biomarketgroup.com>

**BioMarket Group - A Global Online Aggregator of Life Science Market Research**

BioMarket Group  
Björnnäsvägen 21  
11419 STOCKHOLM  
SWEDEN

## Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.biomarketgroup.com/market-research-report/contacts/>

### Order Information

Please verify that the product information is correct:

Product Name: **Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies**

Web Address: <http://www.biomarketgroup.com/market-research-report/triple-analysis-apoptosis-protein-kinase-inhibitors-and-antibodies.html>

Format: PDF

Price: 4495 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

Delivery within Sweden is subject to VAT at 25%.

### Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: \_\_\_\_\_

Name: \_\_\_\_\_

Email Address:\* \_\_\_\_\_

Job Title: \_\_\_\_\_

Organization: \_\_\_\_\_

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

Address: \_\_\_\_\_

Zip Code: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_

Country: \_\_\_\_\_

Phone Number: \_\_\_\_\_

Fax Number: \_\_\_\_\_

### Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
  - Master Card
  - Visa

Cardholder Name: \_\_\_\_\_

Expiry Date (MM/YY): \_\_\_\_\_

Card Number: \_\_\_\_\_

CVV Number: \_\_\_\_\_

- Pay by check:**

Please post the check, accompanied by this form, to:  
BioMarket Group  
Björnnäsvägen 21  
11419 STOCKHOLM  
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: \_\_\_\_\_

Please supply purchase order number if needed:

\* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/>

**Please fax this form to: +46-8-56849191**